Product Name: Ipamorelin Acetate
Cas No: 170851-70-4
Molar Mass: 711.85
Chemical Formula: C38H49N9O5
Synonyms: NNC 26-0161
Storage: Store at -20°C
Sequence: XHAFK
Target: Growth hormone secretagogue receptors
Target Indicators: Growth hormone secretagogue receptors
Purity: 98%
Application:
Ipamorelin acetate is a synthetic peptide belonging to the growth hormone secretagogue (GHS) family. It stimulates the release of growth hormone (GH) from the pituitary gland by activating the ghrelin receptor. In pharmaceutical chemistry, Ipamorelin acetate is studied for its potential therapeutic applications in promoting growth and development, particularly in children with growth hormone deficiency. Additionally, it is investigated for its ability to enhance muscle growth, improve muscle tone, and reduce fat accumulation, making it a promising candidate for treating conditions such as sarcopenia and obesity. In sports medicine, Ipamorelin acetate is used to enhance athletic performance, increase muscle mass, and aid in recovery from strenuous exercise. Its selective action on GH release with minimal effects on other hormones makes it a safer and more targeted option compared to traditional growth hormone therapies.
Current Research:
Ipamorelin, a pentapeptide and a prototype of the growth hormone-releasing peptide (GHRP) receptor-active GH secretagogues (GHS), has garnered attention for its potent and efficacious GH secretagogue properties. Unlike some other GHRPs, Ipamorelin demonstrates no apparent adverse effects on the release of other pituitary hormones and induces longitudinal bone growth along with an increase in body weight. Acting similarly to GHRP6, Ipamorelin stimulates GH release through a GHS-type receptor, with its effects inhibited by GHS receptor antagonists. However, chronic administration of Ipamorelin may lead to partial desensitization of the GHS receptor, attenuating the GH response. The mechanism of GHS-induced GH release involves direct stimulation of somatotroph cells and indirect stimulation through the hypothalamus, possibly involving growth hormone-releasing hormone (GHRH) neurons. The therapeutic potential of GHRPs, including Ipamorelin, in patients with intact hypothalamic function is being explored, aiming to induce a more physiological pattern of GH release without bypassing the feedback loop controlling the GH/IGF-1 axis. Despite the well-tolerated nature of GHRP treatment, chronic administration may lead to desensitization of the GH response and other collateral effects, necessitating further understanding before replacing conventional GH treatment. In a recent study investigating Ipamorelin’s effects, chronic treatment led to increased body weight and stimulated basal GH release in vitro in young female rats. Notably, pretreatment with Ipamorelin alone stimulated the basal GH response in vitro, suggesting a lack of desensitization of somatotroph cells. However, pretreatment with GHRH resulted in desensitization of GH release in vitro. These findings underscore the complexity of GHRP actions and highlight Ipamorelin’s potential as a therapeutic agent, warranting further investigation into its mechanisms and clinical applications.
Reference:
